“BNT211 continues to show encouraging antitumor activity in patients with CLDN6-positive relapsed or refractory advanced solid tumors” <- interesting because they finally demo some effect in solid tumors in humans
“Follow-up of efficacy data at 1x108 CAR-T cells with or without CARVac shows an overall response rate (“ORR”) of 59% and a disease control rate (“DCR”) of 95%, with the CARVac cohort demonstrating a prolonged persistence of CAR-T cells” <- interesting because those are high response rate. Let’s hope it lasts and they can increase those rates but as a patient, you would take this.
“BNT211 continues to show encouraging antitumor activity in patients with CLDN6-positive relapsed or refractory advanced solid tumors” <- interesting because they finally demo some effect in solid tumors in humans
“Follow-up of efficacy data at 1x108 CAR-T cells with or without CARVac shows an overall response rate (“ORR”) of 59% and a disease control rate (“DCR”) of 95%, with the CARVac cohort demonstrating a prolonged persistence of CAR-T cells” <- interesting because those are high response rate. Let’s hope it lasts and they can increase those rates but as a patient, you would take this.